Search
Beigene Ltd
ONCAdd to Watchlist
315.970USD
-6.110-1.90%
Close 07-31 16:00（ET）Quotes delayed by 15 min
32.31BMarket Cap
67.69P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Beigene Ltd is 8.30, ranking 142 out of 385 in the Biotechnology & Medical Research industry. The average price target is 396.00, with a high of 448.00 and a low of 250.00.
Analyst Rating
Based on
28
analysts
Buy
Current Rating
406.958
Target Price
+24.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Beigene Ltd
ONC
28
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Beigene Ltd's expected revenue for the next quarter?
Beigene Ltd's expected revenue is 1.60B.
What is Beigene Ltd's price target?
Analysts forecast that Beigene Ltd's price target is USD 396.00, with the highest forecast at USD 448.00 and the lowest forecast at USD 250.00.
How have Beigene LtdONC's recent earnings per share performed?
The market expectation was USD 2.05, while Beigene LtdONC's earnings per share (EPS) for the previous quarter was USD 0.60. EPS for the next quarter is expected at USD 1.57.
What is the analyst rating for Beigene Ltd?
Based on the ratings of Beigene Ltd's stock from 28 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.